Olema Pharmaceuticals, Inc. - 10-Q Filing
Olema Pharmaceuticals filed its 10-Q for the quarter ended March 31, 2026. The filing includes details on equity incentive plans, stock options, and employee stock purchase plans through 2026. It also references a warrant exchange agreement with Novartis from November 29, 2024, an at-the-market offering sales agreement with T.D. Securities LLC effective January 1, 2025, and amendments to its senior secured loan facility in June 2024.
Tickers: $OLMA